The LancetOriginal article
[Articles] Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial
Phase 3negativeatezolizumabNegative
AI Analysis
Summary
Phase 3 trial (SWOG/NRG S1914) of atezolizumab combined with stereotactic body radiation therapy failed to show improvement in overall survival versus radiation alone in high-risk, early-stage NSCLC, with increased adverse events in the combination arm.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
No improvement in overall survival with atezolizumab plus SBRT compared to radiation alone; increased grade 3 or higher adverse events reported
Importance:7/10
Sentiment:
-0.80
Phase 3NSCLCimmunotherapynegative trial resultsafety concernsstereotactic body radiation therapy
Related Companies
Read the original article
Published by The Lancet on September 6, 2026 10:30 PM